Introduction {#section1-1179299X19860815}
============

Malignant transformation of the ovarian surface epithelium causes epithelial ovarian cancer.^[@bibr1-1179299X19860815]^ Ovarian cancer is 1 of the seventh most common cancer affecting women worldwide and accounting for 295 414 new cases and 184 799 deaths annually.^[@bibr2-1179299X19860815]^ The lifetime risk of developing ovarian cancer in a woman is 1 in 75, with her chance of mortality due to the disease being 1 in 100.^[@bibr3-1179299X19860815]^ It occurs in peri-menopausal and post-menopausal women, with 80% to 90% of cases occurring after the age of 40 with the peak incidence of occurring at age of 60.^[@bibr4-1179299X19860815]^ Other risk factors for cancer include family history, *BRCA1* and *BRCA2* mutations, Lynch II syndrome, infertility, nulliparity, early menarche and late menopause.^[@bibr5-1179299X19860815]^ The familial cases account for only 10% to 15% of the patients while most cases are sporadic.^[@bibr6-1179299X19860815],[@bibr7-1179299X19860815]^ Studies have consistently reported the use of oral contraceptives as being inversely associated with the risk of ovarian cancer, with a protective effect increasing with longer duration of use.^[@bibr8-1179299X19860815],[@bibr9-1179299X19860815]^

Ovarian cancer is staged according to the FIGO system (*Fédération Internationale de Gynécologie et d'Obstétrique*) that considers the extent of tissue involvement, lymph node status and the magnitude of metastasis.^[@bibr10-1179299X19860815]^ Accordingly, stage I and stage II cancers limited to the pelvic cavity are called early stage cancer and the stage III and stage IV cancers that spread beyond the pelvic cavity are called advanced stage cancer.^[@bibr11-1179299X19860815]^ Early detection of ovarian cancer provides an opportunity for successful treatment; however, the disease is rarely diagnosed at an early stage due to lack of symptoms during the early stage. Only one-fourth of the patients present with the disease localized to the ovaries when the 5-year survival rate is 92%, while in contrast more than 75% patients present with the advanced stage disease, with a 5-year survival ranging from 15% to 25%.^[@bibr12-1179299X19860815],[@bibr13-1179299X19860815]^ As most patients are diagnosed with advanced stage of the disease, it leads to a high fatality-to-case ratio among all gynaecologic malignancies.^[@bibr5-1179299X19860815]^

The standard treatment for advanced ovarian cancer is primary cytoreductive surgery followed by platinum-based chemotherapy.^[@bibr14-1179299X19860815]^ The cytoreductive surgery is done to accurately establish a diagnosis, to remove poorly perfused tissue that may harbour the disease and to decrease the tumour bulk to enhance adjuvant chemotherapy.^[@bibr15-1179299X19860815],[@bibr16-1179299X19860815]^ The amount of residual disease after surgery is inversely related to overall survival (OS); patients with optimum cytoreduction (defined as \<1 cm residual disease) having a more superior outcome compared with those with sub-optimal cytoreduction (\>1 cm residual disease).^[@bibr17-1179299X19860815]^ The chemotherapeutic strategy for treating advanced ovarian cancer comprises different chemotherapeutic drugs, and different combinations that have been tried to improve clinical response (CR) and OS and decrease toxicity.^[@bibr18-1179299X19860815]^ The chemotherapeutic regimens used to treat advanced ovarian cancer are comprehensively summarized in [Table 1](#table1-1179299X19860815){ref-type="table"} and the important and most pertinent aspects of various combinations have been discussed below.

###### 

First-line chemotherapeutic regimens in advanced ovarian cancer.

![](10.1177_1179299X19860815-table1)

  Chemotherapy combinations                                      Clinical response   Median PFS (in months)   Overall survival (in months)   Reference
  -------------------------------------------------------------- ------------------- ------------------------ ------------------------------ ---------------------------------------------------------
  Melphalan                                                      20.0%               7.7                      12.3                           ^[@bibr19-1179299X19860815],[@bibr20-1179299X19860815]^
  Melphalan hexamethylmelamine                                   28.0%               6.0                      13.5                           ^[@bibr19-1179299X19860815]^
  Cyclophosphamide doxorubicin                                   32.0%               9.5                      14.2                           ^[@bibr19-1179299X19860815]^
  Cyclophosphamide doxorubicin                                   26.0%               7.7                      15.7                           ^[@bibr21-1179299X19860815]^
  Carboplatin Etoposide                                          43.0%               8.5                      19.5                           ^[@bibr22-1179299X19860815]^
  Carboplatin Hexamethylmelamine Etoposide                       92.0%               --                       --                             ^[@bibr23-1179299X19860815]^
  Cisplatin Cyclophosphamide                                     60.0%               17.9                     24.4                           ^[@bibr24-1179299X19860815]^
  Cisplatin Cyclophosphamide                                     60.0%               13.0                     24.0                           ^[@bibr24-1179299X19860815]^
  Cisplatin Cyclophosphamide                                     16.0%               19.0                     35.0                           ^[@bibr25-1179299X19860815]^
  Cisplatin Cyclophosphamide Doxorubicin                         51.0%               13.1                     19.7                           ^[@bibr21-1179299X19860815]^
  Cisplatin Paclitaxel                                           73.0%               18.0                     38.0                           ^[@bibr24-1179299X19860815]^
  Cisplatin Paclitaxel                                           81.4%               19.1                     44.1                           ^[@bibr26-1179299X19860815]^
  Cisplatin Ifosfamide                                           69.0%               14.0                     25.0                           ^[@bibr27-1179299X19860815]^
  Cisplatin Ifosfamide                                           67.5%               --                       --                             ^[@bibr28-1179299X19860815]^
  Paclitaxel                                                     55.0%               6.1                      --                             ^[@bibr29-1179299X19860815]^
  Carboplatin Cyclophosphamide                                   14.0%               26.0                     37.0                           ^[@bibr25-1179299X19860815]^
  Carboplatin Ifosfamide                                         67.0%                                        24.9                           ^[@bibr30-1179299X19860815]^
  Carboplatin Paclitaxel Hexamethylmelamine                      76.0%               --                       --                             ^[@bibr31-1179299X19860815]^
  Cisplatin Docetaxel                                            69.0%               --                       --                             ^[@bibr32-1179299X19860815]^
  Cisplatin Docetaxel                                            58.0%               14.4                     43.0                           ^[@bibr33-1179299X19860815]^
  Cisplatin thio-TEPA                                            80.0%               12.0                     18.0                           ^[@bibr34-1179299X19860815]^
  Cisplatin Paclitaxel Topotecan                                 60.0%               --                       --                             ^[@bibr35-1179299X19860815]^
  Carboplatin Paclitaxil Epirubicin                              86.0%               18.7                     --                             ^[@bibr36-1179299X19860815]^
  Carboplatin Paclitaxil Epirubicin                              90.0%               --                       65.0                           ^[@bibr37-1179299X19860815]^
  Carboplatin Paclitaxel Etoposide Cyclophosphamide with G-CSF   92.0%               4.0                      --                             ^[@bibr38-1179299X19860815]^
  Cisplatin Paclitaxel Ifosfamide                                85.0%               22.2                     52.8                           ^[@bibr39-1179299X19860815]^
  Cisplatin Paclitaxel Ifosfamide                                85.0%               --                       51.0                           ^[@bibr37-1179299X19860815]^
  Carboplatin Paclitaxel Gemcitabine                             94.0%               16.0                     28.0                           ^[@bibr40-1179299X19860815]^
  Carboplatin Paclitaxel Gemcitabine                             97.5%               19.5                     31.2                           ^[@bibr41-1179299X19860815]^
  Cisplatin Gemcitabine                                          70.7%               10.4                     23.4                           ^[@bibr42-1179299X19860815]^
  Cisplatin Gemcitabine                                          64.9%               13.4                     24.0                           ^[@bibr43-1179299X19860815]^
  Cisplatin Irinotecan                                           76.0%               --                       30.9                           ^[@bibr44-1179299X19860815]^
  Carboplatin Paclitaxel Epidoxorubicin                          86.0%               19.5                     36.0                           ^[@bibr45-1179299X19860815]^
  Carboplatin Docetaxel                                          73.0%               18.0                     24.4                           ^[@bibr46-1179299X19860815]^
  Carboplatin Docetaxel                                          78.8%               12.0                     35.3                           ^[@bibr47-1179299X19860815]^
  Carboplatin Paclitaxel Topotecan                               77.0%               10.6                     22.2                           ^[@bibr48-1179299X19860815]^
  Carboplatin Paclitaxel Amifostine                              38.0%               22.0                     --                             ^[@bibr49-1179299X19860815]^
  Carboplatin Paclitaxel Etoposide                               75.0%               12.0                     24.0                           ^[@bibr50-1179299X19860815]^
  Carboplatin Gemcitabine                                        83.3%               11.6                     29.2                           ^[@bibr51-1179299X19860815]^
  Carboplatin Paclitaxel Gemcitabine Oxaliplatin                 85.0%               14.5                     31.5                           ^[@bibr52-1179299X19860815]^
  Carboplatin Paclitaxel Epirubicin                              60.1%               18.4                     45.8                           ^[@bibr53-1179299X19860815]^
  Carboplatin Paclitaxel Epirubicin                              65.7%               16.4                     42.4                           ^[@bibr54-1179299X19860815]^
  Carboplatin Paclitaxel Bevacizumab                             80.0%               --                       --                             ^[@bibr55-1179299X19860815]^
  Carboplatin Paclitaxel Bevacizumab                             48.0%               16.9                     29.9                           ^[@bibr56-1179299X19860815]^
  Carboplatin Topotecan                                          71.0%               --                       47.0                           ^[@bibr57-1179299X19860815]^
  Cisplatin Paclitaxel Doxorubicin                               64.0%               18.1                     44.3                           ^[@bibr58-1179299X19860815]^
  Carboplatin Doxorubicin                                        57.0%               19.0                     61.6                           ^[@bibr59-1179299X19860815]^
  Carboplatin Paclitaxel lonafarnib                              --                  11.5                     20.6                           ^[@bibr60-1179299X19860815]^
  Oxaliplatin Docetaxel Bevacizumab                              58.6%               16.3                     47.3                           ^[@bibr61-1179299X19860815]^
  Carboplatin Paclitaxel Sorafenib                               69.0%               15.4                     --                             ^[@bibr62-1179299X19860815]^

Abbreviations: G-CSF, granulocyte colony stimulating factor; PFS, progression-free survival.

Melphalan as a Single Agent and Its Combinations {#section2-1179299X19860815}
================================================

During the 1950s, the main therapeutic strategy for treating advanced ovarian cancer was cytoreductive surgery and radiotherapy. An improvement in the treatment was achieved with the use of alkylating agents like melphalan which causes cytotoxicity against tumour cells by alkylating DNA at N7 position of guanine and induces DNA inter-strand cross-linkages, leading to inhibition of replication and transcription.^[@bibr63-1179299X19860815]^ The use of single-agent melphalan benefitted the patients with advanced ovarian cancer.^[@bibr64-1179299X19860815]^ However, the CR was 20%, median progression-free survival (median PFS) was 7.7 months and median OS was 12.3 months, along with toxicity manifestations such as myelosuppression with neutropenia.^[@bibr19-1179299X19860815],[@bibr20-1179299X19860815]^ The combination of melphalan and hexamethylmelamine produced a CR of 28%, median PFS of 6 months and median OS of 13.5 months as compared with the combination of adriamycin and cyclophosphamide, which produced a slightly improved CR of 32%, median PFS of 9.5 months and median OS of 14.2 months; however, it produced significant hematologic and gastrointestinal toxicity.^[@bibr19-1179299X19860815]^ The use of melphalan is limited as it causes severe myelosuppression.^[@bibr65-1179299X19860815]^

Cyclophosphamide as a Single Agent and Its Combinations {#section3-1179299X19860815}
=======================================================

Previous studies have demonstrated the efficacy of other alkylating agents like cyclophosphamide and anthracycline doxorubicin. The *GOG* (*Gynecologic Oncology Group*) trial comparing cyclophosphamide, melphalan and doxorubicin demonstrated an improvement in response rate; however, there was no OS advantage.^[@bibr19-1179299X19860815]^ Clinical trials studying the effect of this combination have shown a CR of 26% and median OS of 15.7 months with side effects such as nausea, vomiting and leukocyte toxicity.^[@bibr21-1179299X19860815]^

Cisplatin as a Single Agent and Its Combinations {#section4-1179299X19860815}
================================================

The inclusion of cisplatin in the chemotherapeutic regimen for advanced ovarian cancer proved to be a major landmark. Cisplatin binds to nuclear DNA leading to interference with transcription and/or DNA replication and eventually cell death induced by cell repair machinery.^[@bibr66-1179299X19860815]^ A Cochrane review and meta-analysis confirmed a modest 2- and 5-year survival advantage in women with advanced stage epithelial ovarian cancer who were given platinum-based combination chemotherapy compared with those given combination therapy lacking platinum.^[@bibr67-1179299X19860815]^ The use of cisplatin in combination with thio-TEPA produced an improved CR; however, OS was not good.^[@bibr34-1179299X19860815]^ The combination of cisplatin, cyclophosphamide and doxorubicin showed an increased CR of 51% and median OS of 19.7 months.^[@bibr21-1179299X19860815]^ Chemotherapy combinations containing an alkylating agent and a platinum coordination complex produced a high response rate in women with advanced ovarian cancer. Cisplatin-based combination chemotherapy showed improved CR and progression-free interval (PFS) as compared with alkylating agents alone or combinations without cisplatin.^[@bibr24-1179299X19860815]^ The CR in the cisplatin-cyclophosphamide group was 60% and median OS was of 24.4 months.^[@bibr24-1179299X19860815]^ As long-term disease control in patients with advanced ovarian cancer was not significant, new drug combinations were investigated. The efficacy of cisplatin-ifosfamide combination showed improved CR and OS.^[@bibr27-1179299X19860815],[@bibr28-1179299X19860815]^ Cisplatin-docetaxel combination produced an improved CR of 69%; however, increasing the docetaxel dose caused significant hematologic toxicity to the patient.^[@bibr32-1179299X19860815],[@bibr33-1179299X19860815]^ Cisplatin with gemcitabine, a nucleoside antimetabolite, is an active agent in ovarian cancer and produced significantly increased CR.^[@bibr42-1179299X19860815],[@bibr43-1179299X19860815]^ A similar study reported a 71% CR; however, 63% of patients developed high-grade neutropenia and 28% developed high-grade thrombocytopenia.^[@bibr68-1179299X19860815]^ The combination of cisplatin with irinotecan, an inhibitor of DNA topoisomerase I, showed improved activity in chemotherapy-naive patients with advanced ovarian cancer; however, neutropenia was the dose-limiting adverse effect.^[@bibr44-1179299X19860815],[@bibr69-1179299X19860815]^

Carboplatin as a Single Agent and Its Combinations {#section5-1179299X19860815}
==================================================

Carboplatin which has good efficacy and less toxicity than cisplatin was introduced in the 1980s as first-line chemotherapeutic agent.^[@bibr66-1179299X19860815],[@bibr70-1179299X19860815]^ Carboplatin crosses the cell membrane where it is hydrolysed to 1,1-cyclobutanedicarboxylate and therefore gains a positive charge.^[@bibr71-1179299X19860815],[@bibr72-1179299X19860815]^ The positively charged intermediate interacts with nucleophilic molecules such as DNA or RNA by covalent bond formation with the N7 site of purine bases leading to formation of platinum adducts ([Figure 1](#fig1-1179299X19860815){ref-type="fig"}).^[@bibr73-1179299X19860815],[@bibr74-1179299X19860815]^ Carboplatin is less toxic than cisplatin as the former forms an intermediate 1,1-cyclobutanedicarboxylate which is a poorer leaving group as compared with chloride, which leads to low reactivity rate and there is therefore less adduct formation.^[@bibr75-1179299X19860815]^ The clearance of cisplatin occurs majorly by host tissues; however, for carboplatin, it occurs by renal function, therefore targeted area-under-the-curve (AUC) dosing based on estimated renal clearance improved safety and tolerability of carboplatin.^[@bibr76-1179299X19860815]^ Carboplatin and etoposide, which showed significant synergistic activity in animal models of ovarian cancer, had a relatively low CR of only 43% along with increased toxicity rate.^[@bibr22-1179299X19860815]^ Combination of carboplatin, hexamethylmelamine and etoposide produced a very high CR of 92%; however, the study was on a very small sample size.^[@bibr23-1179299X19860815]^ Carboplatin and cyclophosphamide combination proved to be effective in optimally debulked advanced ovarian cancer patients; however, the combination did not significantly prevent tumour progression in a majority of patients.^[@bibr25-1179299X19860815]^ A combination of carboplatin and ifosfamide too has showed improved CR.^[@bibr30-1179299X19860815]^ Carboplatin and docetaxel produced an improved CR of 73%; however, it has substantial myelotoxicity.^[@bibr46-1179299X19860815]^ Gemcitabine, a nucleoside analogue, and carboplatin also showed significant CR.^[@bibr51-1179299X19860815]^ Carboplatin and topotecan, which is a specific topoisomerase I inhibitor that causes single-stranded breaks in DNA during replication, showed a CR of 71%.^[@bibr57-1179299X19860815]^

![Mechanism of action of cisplatin. Double stranded DNA is shown in black; Cisplatin is shown as a brown oval; and purine bases are shown as blue coloured lines.](10.1177_1179299X19860815-fig1){#fig1-1179299X19860815}

Paclitaxel as a Single Agent and Its Combinations {#section6-1179299X19860815}
=================================================

In the 1990s, paclitaxel was found to be the most effective agent in patients with relapsed platinum-refractory disease.^[@bibr77-1179299X19860815]^ It acts by binding to intracellular β-tubulin, which leads to microtubule stabilization, *G2-M* arrest and apoptosis, via both p53-dependent and p53-independent pathways.^[@bibr78-1179299X19860815]^ Earlier the most commonly used combination was cyclophosphamide and cisplatin; however, the OS was not sufficient. At this stage, paclitaxel was included in first-line chemotherapy for patients with sub-optimally debulked advanced ovarian cancer which led to increase in the duration of the PFS and OS.^[@bibr24-1179299X19860815]^ Paclitaxel used alone emerged as an effective and safe drug for first-line treatment of advanced ovarian cancer.^[@bibr29-1179299X19860815]^ Paclitaxel-cisplatin produces an overall higher CR although it has low tolerability than the conventional combination of carboplatin-paclitaxel.^[@bibr24-1179299X19860815],[@bibr26-1179299X19860815]^ A GOG study along with other randomized studies concluded that the inclusion of paclitaxel with a platinum analogue produced significant improvement in response and survival.^[@bibr24-1179299X19860815],[@bibr79-1179299X19860815]^ At this stage, combination of paclitaxel, cisplatin and ifosfamide was investigated which produced a CR of 85%.^[@bibr39-1179299X19860815]^ Paclitaxel, cisplatin and doxorubicin combination produced a CR of 64%, a marginal improvement in PFS; however, there was improved survival benefit when compared with the standard carboplatin-paclitaxel combination.^[@bibr58-1179299X19860815]^ It may be noted here that combinations of paclitaxel and carboplatin along with a third agent have also been tested across various clinical trials ([Table 1](#table1-1179299X19860815){ref-type="table"}). However, these combinations have had their own limitations like no improvement in CR as compared with carboplatin and paclitaxel, increased haematological toxicities, neutropenia, alopecia and thrombocytopenia.^[@bibr53-1179299X19860815],[@bibr80-1179299X19860815],[@bibr81-1179299X19860815]^

Carboplatin and Paclitaxel as a Combination {#section7-1179299X19860815}
===========================================

Carboplatin and paclitaxel have been a standard chemotherapy combination used and the related clinical studies summarizing its efficacy are provided in [Table 2](#table2-1179299X19860815){ref-type="table"}. It is seen that the combination therapy of carboplatin-paclitaxel achieves a CR ranging from 50% to 81% and median PFS range of 13.6 to 19.3 months. Numerous trials have established that a combination of paclitaxel and carboplatin is well tolerated in advanced ovarian cancer.^[@bibr90-1179299X19860815]^ A few earlier randomized trials too demonstrated that the combination of cisplatin and paclitaxel was superior to cisplatin and cyclophosphamide in advanced ovarian cancer.^[@bibr91-1179299X19860815]^ Also, trials have showed that carboplatin and paclitaxel was a less toxic and highly effective combination regimen.^[@bibr92-1179299X19860815]^ A study conducted by *GOG* in patients with optimally debulked advanced ovarian cancer revealed that the median PFS and OS were 19.4 and 48.7 months, respectively, for the cisplatin-paclitaxel as compared with 20.7 and 57.4 months, respectively, for carboplatin-paclitaxel. In addition, gastrointestinal, renal, metabolic toxicity and leukopenia were significantly more in cisplatin-paclitaxel group as compared with carboplatin-paclitaxel.^[@bibr92-1179299X19860815]^ Another clinical trial compared carboplatin-paclitaxel and carboplatin, paclitaxel and cisplatin combination. The median PFS and OS were not statistically different, although carboplatin-paclitaxel combination was associated with better tolerability and quality of life (median PFS: 17.2 vs 19.1 months; median OS: 43.3 vs 44.1 months). The mean global quality-of-life scores at the end of treatment were statistically significantly better with the use of carboplatin-paclitaxel (65.25 vs 51.97).^[@bibr26-1179299X19860815]^ In the HeCOG (Hellenic Cooperative Oncology Group) study comparing carboplatin-paclitaxel and cisplatin, paclitaxel and doxorubicin, the latter showed a slight increase in PFS; however, there was no additional survival benefit (CR: 69% vs 64%; median PFS: 13.25 vs 18.13 months; median OS: 37.97 vs 44.33 months).^[@bibr58-1179299X19860815]^ Previous trials comparing cisplatin and paclitaxel against carboplatin and paclitaxel, 1 using different paclitaxel schedules on the 2 arms suggested that carboplatin and paclitaxel had more favourable toxicity proﬁle and convenience of a shorter schedule.^[@bibr93-1179299X19860815],[@bibr94-1179299X19860815]^ Other studies have demonstrated that quality of life was better during treatment with carboplatin and paclitaxel as compared with cisplatin and paclitaxel.^[@bibr95-1179299X19860815],[@bibr96-1179299X19860815]^ Such landmark studies established the combination of carboplatin-paclitaxel as the standard of care in advanced ovarian cancer.

###### 

First-line chemotherapeutic treatment with carboplatin-paclitaxel in advanced ovarian cancer.

![](10.1177_1179299X19860815-table2)

  Clinical response   Median PFS (in months)   Overall survival (in months)   Reference
  ------------------- ------------------------ ------------------------------ ------------------------------
  57.0%               --                       --                             ^[@bibr82-1179299X19860815]^
  75.0%               --                       --                             ^[@bibr83-1179299X19860815]^
  70.0%               --                       --                             ^[@bibr83-1179299X19860815]^
  57.0%               --                       --                             ^[@bibr25-1179299X19860815]^
  74.0%               --                       --                             ^[@bibr84-1179299X19860815]^
  81.0%               --                       20.0                           ^[@bibr85-1179299X19860815]^
  50.0%               --                       --                             ^[@bibr86-1179299X19860815]^
  67.7%,              17.2                     43.3                           ^[@bibr26-1179299X19860815]^
  60.0%               17.9                     41.0                           ^[@bibr53-1179299X19860815]^
  69.0%               18.1                     38.0                           ^[@bibr58-1179299X19860815]^
  77.5%               19.3                     51.5                           ^[@bibr87-1179299X19860815]^
  59%                 16.8                     53.2                           ^[@bibr88-1179299X19860815]^
  80.0%               16.0                     40.2                           ^[@bibr54-1179299X19860815]^
  56.2%               18·3                     --                             ^[@bibr89-1179299X19860815]^
  74.0%               16.3                     --                             ^[@bibr62-1179299X19860815]^

Abbreviation: PFS, progression-free survival.

Chemotherapy Resistance in Advanced Ovarian Cancer {#section8-1179299X19860815}
==================================================

First-line chemotherapy with carboplatin and paclitaxel achieves an improved CR; however, recurrence occurs in 25% of patients with early stage disease and more than 80% of patients with advanced disease.^[@bibr97-1179299X19860815]^ A majority of advanced ovarian cancer patients experience disease relapse within 2 years of the initial treatment of combination chemotherapy.^[@bibr98-1179299X19860815]^ The heterogeneity of tumour cells leads to molecular variations in signalling pathways including oncogene activation, tumour suppressor inactivation and various pro-survival genetic mutations.^[@bibr99-1179299X19860815]^ Therefore, chemo-resistance to standard chemotherapy regimen has emerged as a major challenge.^[@bibr100-1179299X19860815]^ Whereas the current therapeutic regimens are fixed linear protocols, cancer biology is a highly dynamic system. Adapting a therapeutic strategy using systems biology approach based on temporal and spatial variations in tumour is a futuristic goal in oncology.^[@bibr101-1179299X19860815]^ Other studies including poly (ADP-ribose) polymerase inhibitors and anti-angiogenic agents have shown that trial design with restricted eligibility criteria rather than testing chemotherapeutic agents in unselected populations can lead to improved clinical outcomes in the targeted populations.^[@bibr102-1179299X19860815][@bibr103-1179299X19860815]--[@bibr104-1179299X19860815]^ Drug resistance is 1 of the most important factors for failure of chemotherapy in advanced ovarian cancer. Chemotherapy resistance is of 2 types: (a) intrinsic chemo-resistance, where the cancer cells are inherently resistant to drug treatment, and (b) acquired chemo-resistance, which can be acquired during the course of treatment.^[@bibr105-1179299X19860815]^ Intrinsic chemo-resistance is caused due to cancer cells possessing several biological modifications including inhibited drugs uptake, increased drug efflux, increased detoxification of chemotherapeutic drugs, inhibition of apoptosis and so on.^[@bibr106-1179299X19860815]^ While acquired chemo-resistance can arise due to genetic and epigenetic alternations that assist the cancer cells to adapt to chemotherapy induced effects such as stress, DNA damage and apoptosis.^[@bibr106-1179299X19860815]^ Therefore, chemo-resistance, which is a multifactorial phenomenon, is being investigated with the view to decipher chemo-resistance mechanisms and develop drugs to overcome it.^[@bibr107-1179299X19860815],[@bibr108-1179299X19860815]^ However, the major problem is that identification of patients pre-disposed to chemo-resistance is challenging as there are no available tests to guide clinicians to make an informed decision to alter treatment course before chemotherapy.

Biomarkers and Chemotherapy Resistance in Advanced Ovarian Cancer {#section9-1179299X19860815}
=================================================================

Despite initial responsiveness to combination chemotherapy of carboplatin and paclitaxel, the occurrence of chemo-resistant tumours is a major hurdle and therefore demands elucidation of its pathogenesis. The delineation of molecular signatures from these tissues has paved the way for biomarker discovery. Biomarkers are biological macromolecules that can be objectively measured and evaluated and indicate the functioning of biological processes and pharmacologic response in the human body.^[@bibr109-1179299X19860815]^ Biomarker discovery has made many strides in the field of medicine and health.^[@bibr110-1179299X19860815][@bibr111-1179299X19860815]--[@bibr112-1179299X19860815]^ Over the past decade, clinical proteomics has helped in biomarker discovery in the field of advanced ovarian cancer.^[@bibr113-1179299X19860815],[@bibr114-1179299X19860815]^ An understanding of biomarkers in chemotherapy resistance in advanced ovarian cancer will have the following benefits: (a) to elucidate the molecular mechanisms at a cellular level that dictate drug resistance, (b) design new therapeutic strategies to overcome drug resistance, (c) plan the best chemotherapeutic strategy and improve patient management, (d) help to improve patient compliance and reduce financial expenditure and (e) predict the sensitivity of tumour to chemotherapeutic regimen allowing chemotherapy administration to the patient who would benefit and prevent the toxic effects of chemotherapy to non-responder patients.

Various biomarkers and their mechanism of action that help to understand chemotherapy resistance are summarized in [Table 3](#table3-1179299X19860815){ref-type="table"}. Even though chemo-resistance has plagued the CR and survival in advanced ovarian cancer since the beginning of chemotherapy administration, the research investigating predictive biomarkers began much later. It can be observed that much of the research in chemo-resistance biomarker discovery has focussed on transcriptomics and proteomics with very few genomic studies investigating the same.

###### 

Biomarkers for chemo-resistance to first-line chemotherapy in advanced ovarian cancer.

![](10.1177_1179299X19860815-table3)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Chemotherapy                                             Macromolecule        Biomarker                                                        Source                          Cellular mechanism                                                                                                                                                                         Clinical phenotype   Chemo-resistance   References
  -------------------------------------------------------- -------------------- ---------------------------------------------------------------- ------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------- ------------------ ---------------------------------------------------------------------------------------
  Platinum-based drug/Alkylating agent                     Protein              Lung resistance protein (*LRP*) ↑                                Tissue                          Increases drug efflux                                                                                                                                                                      Non-responder        Intrinsic          ^[@bibr115-1179299X19860815]^

  Doxorubicin, cisplatin and paclitaxel                    *mRNA*               Human epidermal growth factor receptor 2 (*HER-2*) ↑             Cell line                       Increases drug efflux and increases drug metabolism                                                                                                                                        Responder            N/A                ^[@bibr116-1179299X19860815],[@bibr117-1179299X19860815]^

  Paclitaxel                                               RNA                  Inactive X chromosome-specific Transcripts (*XIST*) ↓            Cell line and tissue            Reactivates resistance-specific genes on inactive X chromosome in the absence of *XIST*\                                                                                                   Non-responder        Acquired           ^[@bibr118-1179299X19860815]^
                                                                                                                                                                                 RNA.                                                                                                                                                                                                                               

  Cisplatin                                                Protein              Cycloxegenase-2 (*COX-2*) ↑                                      Tissue                          Increases proliferation and inhibits apoptosis                                                                                                                                             Non-responder        Intrinsic          ^[@bibr119-1179299X19860815]^

  Cisplatin                                                Protein              P-glycoprotein (*Pgp*) ↑                                         Tissue                          Increases drug efflux                                                                                                                                                                      Non-responder        Intrinsic          ^[@bibr119-1179299X19860815]^

  Cisplatin                                                *mRNA*               Trophinin (*TRO*) ↑                                              Cell line                       Homophilic adhesion molecule involved in blastocyst implantation                                                                                                                           Responder            N/A                ^[@bibr120-1179299X19860815]^

  Carboplatin and cyclophosphamide                         Protein              Excision repair cross-complementation group 1 (*ERCC-1*) ↑       Tissue                          Increases DNA repair                                                                                                                                                                       Non-responder        Intrinsic          ^[@bibr121-1179299X19860815]^

  Platinum-based drug and paclitaxel                       Protein              Vascular endothelial growth factor (*VEGF*) ↑                    Ascites                         Increases tumour angiogenesis                                                                                                                                                              Non-responder        Intrinsic          ^[@bibr122-1179299X19860815]^

  Platinum-based drug and paclitaxel                       Protein              Tumour necrosis factor alpha (*TNFα*) ↑                          Ascites                         Increases inflammation                                                                                                                                                                     Non-responder        Intrinsic          ^[@bibr122-1179299X19860815]^

  Paclitaxel                                               Protein              Endoplasmic reticulum resident oxidoreductase 57 (ERp57) ↑       Cell line                       Increases protein folding under stress and inhibits apoptosis                                                                                                                              Non-responder        Acquired           ^[@bibr123-1179299X19860815]^

  Platinum-based drug and cyclophosphamide or paclitaxel   *mRNA*               Mesothelin (*MSLN*) ↑                                            Tissue                          Alters the time spent by cytotoxic drugs in the peritoneal cavity or changes the tumour microenvironment of ovarian cancer patients; therefore inhibiting the effects of cytotoxic drugs   Non-responder        Intrinsic          ^[@bibr124-1179299X19860815]^

  Cisplatin                                                *DNA*                Insulin-like growth factor I receptor (*IGF1R*) ↑                Cell line                       Inhibits apoptosis                                                                                                                                                                         Non-responder        Acquired           ^[@bibr125-1179299X19860815][@bibr126-1179299X19860815]--[@bibr127-1179299X19860815]^

  Cisplatin                                                *DNA*                Phosphatidylinositol-3-OH kinase (*PIK*) ↑                       Cell line                       Inhibits apoptosis                                                                                                                                                                         Non-responder        Acquired           ^[@bibr125-1179299X19860815][@bibr126-1179299X19860815]--[@bibr127-1179299X19860815]^

  Platinum-based-drug                                      *DNA*                Cyclin E (*CCNE1*) ↑                                             Tissue                          Increases cell proliferation                                                                                                                                                               Non-responder        Intrinsic          ^[@bibr128-1179299X19860815]^

  Paclitaxel                                               Protein              Heterogeneous nuclear riboprotein A2 (*hnRNPA2*) ↓               Cell line                       Increased cell stability                                                                                                                                                                   Non-responder        Acquired           ^[@bibr129-1179299X19860815],[@bibr130-1179299X19860815]^

  Paclitaxel                                               Protein              Rho GDP dissociation inhibitor (*GDI 2*) ↓                       Cell line                       Increases invasion                                                                                                                                                                         Non-responder        Acquired           ^[@bibr129-1179299X19860815],[@bibr131-1179299X19860815]^

  Cisplatin                                                Protein              Pyruvate kinase-M2 (*PKM2*) ↓                                    Cell line                       Increases drug inactivation                                                                                                                                                                Non-responder        Acquired           ^[@bibr132-1179299X19860815],[@bibr133-1179299X19860815]^

  Cisplatin                                                Protein              Heat shock protein D1 (*HSP-D1*) ↑                               Cell line                       Inhibits apoptosis                                                                                                                                                                         Non-responder        Acquired           ^[@bibr132-1179299X19860815],[@bibr134-1179299X19860815]^

  Cisplatin                                                Protein              Hypoxia up-regulated protein 1 precursor (*HYOU1*) ↑             Cell line                       Inhibits apoptosis                                                                                                                                                                         Non-responder        Acquired           ^[@bibr132-1179299X19860815],[@bibr135-1179299X19860815]^

  Cisplatin                                                Protein              Isoform 1 of collagen XII alpha-1 chain (*COL12A1*) ↓            Cell line                       Increases tumour angiogenesis and invasion                                                                                                                                                 Non-responder        Acquired           ^[@bibr132-1179299X19860815],[@bibr136-1179299X19860815],[@bibr137-1179299X19860815]^

  Cisplatin                                                Protein              Calnexin (*CNX*) ↑                                               Cell line                       Inhibits apoptosis                                                                                                                                                                         Non-responder        Acquired           ^[@bibr132-1179299X19860815],[@bibr138-1179299X19860815]^

  Cisplatin                                                Protein              High mobility group protein B1 (*HMGB1*) ↑                       Cell line                       Reduces DNA damage                                                                                                                                                                         Non-responder        Acquired           ^[@bibr132-1179299X19860815],[@bibr139-1179299X19860815]^

  Cisplatin                                                Protein              Lung resistance protein (*LRP*) ↑                                Cell line                       Increases drug efflux                                                                                                                                                                      Non-responder        Acquired           ^[@bibr104-1179299X19860815],[@bibr121-1179299X19860815]^

  Cisplatin                                                Protein              Nestin (*NES*)↑                                                  Tissue                          Increases tumour angiogenesis                                                                                                                                                              Non-responder        Intrinsic          ^[@bibr130-1179299X19860815],[@bibr131-1179299X19860815]^

  Cisplatin                                                Protein              Activated leukocyte cell adhesion molecule (*ALCAM*)↑            Cell line                       Increased interaction with pro-growth NFκB pathway                                                                                                                                         Non-responder        Acquired           ^[@bibr132-1179299X19860815]^

  Cisplatin                                                Protein              A-kinase anchoring protein 12 (*AKAP12*) ↑                       Cell line                       Inhibits apoptosis                                                                                                                                                                         Non-responder        Acquired           ^[@bibr132-1179299X19860815]^

  Carboplatin                                              Protein              Steroid receptor coactivator 3 (*SRC-3*) ↑                       Tissue                          Increases cell survival                                                                                                                                                                    Non-responder        Intrinsic          ^[@bibr114-1179299X19860815],[@bibr133-1179299X19860815]^

  Cisplatin                                                Protein              Pro-alpha1(XI) chain (COL11A1) ↑                                 Cell line                       Increases invasion                                                                                                                                                                         Non-responder        Acquired           ^[@bibr134-1179299X19860815],[@bibr135-1179299X19860815]^

  Paclitaxel                                               *mRNA*               Chitinase 3-like 1 (*CHI3L1*) ↑                                  Tissue                          Inhibits apoptosis                                                                                                                                                                         Non-responder        Intrinsic          ^[@bibr136-1179299X19860815]^

  Platinum-based drug and paclitaxel                       *mRNA*               Insulin-like growth factor 2 mRNA-binding protein (*IGF2BP*) ↑   Tissue                          Increases tumour proliferation                                                                                                                                                             Non-responder        Intrinsic          ^[@bibr137-1179299X19860815]^

  Platinum-based and paclitaxel                            *mRNA*               Lin-28 Homolog B (Lin28B) ↑                                      Tissue                          Acts as oncogene by blocking let-7 miRNA biogenesis and subsequent depression of let-7 miRNA target genes                                                                                  Non-responder        Intrinsic          ^[@bibr139-1179299X19860815]^

  Platinum-based drug                                      Protein              Leptin (*LEP*) ↑                                                 Ascites                         Inhibits apoptosis                                                                                                                                                                         Non-responder        Intrinsic          ^[@bibr138-1179299X19860815],[@bibr139-1179299X19860815]^

  Cisplatin paclitaxel                                     Protein              Midkine (*MK*) ↑                                                 Tissue                          Increases cytotoxicity                                                                                                                                                                     Responder            N/A                ^[@bibr140-1179299X19860815]^

  Paclitaxel                                               Protein              Musashi-2 (*MSI2*) ↑                                             Cell line                       Increases drug efflux                                                                                                                                                                      Non-responder        Acquired           ^[@bibr141-1179299X19860815]^

  Platinum-based                                           Protein              RAN Binding Protein 1 (*RANBP1*) ↓                               Tissue                          Increases tumour proliferation, decreases drug binding to DNA and inhibits apoptosis                                                                                                       Non-responder        Intrinsic          ^[@bibr142-1179299X19860815]^

  Platinum-based drug                                      Protein              Actinin Alpha 4\                                                 Tissue                          Increases invasion                                                                                                                                                                         Non-responder        Intrinsic          ^[@bibr142-1179299X19860815]^
                                                                                (*ACTN4*) ↑                                                                                                                                                                                                                                                                                                                         

  Platinum-based drug                                      Protein              Keratin 19 (*KRT19*) ↑                                           Tissue                          Increases invasion                                                                                                                                                                         Non-responder        Intrinsic          ^[@bibr142-1179299X19860815],[@bibr143-1179299X19860815]^

  Platinum-based drug                                      Protein              Lactate dehydrogenase A-like 6A **(***LDHAL6A*) **↑**            Tissue                          Increases anaerobic metabolism                                                                                                                                                             Non-responder        Intrinsic          ^[@bibr142-1179299X19860815],[@bibr144-1179299X19860815]^

  Platinum-based drug                                      Protein              *Thiopurine S-methyltransferase*\                                Tissue                          Decreases metabolism of drug                                                                                                                                                               Responder            N/A                ^[@bibr142-1179299X19860815],[@bibr145-1179299X19860815]^
                                                                                (*TPMT*) ***↓***                                                                                                                                                                                                                                                                                                                    

  Platinum-based and paclitaxel                            Protein              Mesothelium vascular cell adhesion molecule-1 (*VCAM-1*) ↑       Serum                           Increases invasion                                                                                                                                                                         Non-responder        Acquired           ^[@bibr146-1179299X19860815],[@bibr147-1179299X19860815]^

  Platinum-based drug                                      Protein              Epithelial cell adhesion molecule (*EpCam*) ↑                    Tissue                          Inhibits apoptosis                                                                                                                                                                         Non-responder        Acquired           ^[@bibr148-1179299X19860815]^

  Platinum-based drug                                      *mRNA and protein*   Forkhead box M1 (*FOXM1*) ↑                                      Tissue                          Increases cell-cycle progression, response to DNA damage                                                                                                                                   Non-responder        Intrinsic          ^[@bibr149-1179299X19860815],[@bibr150-1179299X19860815]^

  Carboplatin                                              *mRNA and protein*   Keratin 5 (*KRT5*) ↑                                             Cell line, tissue and ascites   Increases cytoskeletal stability                                                                                                                                                           Non-responder        Acquired           ^[@bibr151-1179299X19860815]^

  Cisplatin                                                *mRNA*               Colony-stimulating-factor-1 receptor\                            Cell line                       Inhibits apoptosis                                                                                                                                                                         Non-responder        Acquired           ^[@bibr152-1179299X19860815]^
                                                                                (*CSF-1R*) ↑                                                                                                                                                                                                                                                                                                                        

  Cisplatin                                                *mRNA*               3-Oxoacid CoA transferase 1 (*OXCT1*) ↓                          Cell line                       Inhibits apoptosis                                                                                                                                                                         Non-responder        Acquired           ^[@bibr153-1179299X19860815],[@bibr154-1179299X19860815]^
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The field of genomics encompasses the systematic study of the genome of an organism. In advanced ovarian cancer, genomics has been primarily used to reveal chromosomal abnormalities or mutations such as insertions and deletions or abnormal chromosomal numbers in a process.^[@bibr125-1179299X19860815],[@bibr128-1179299X19860815],[@bibr155-1179299X19860815],[@bibr156-1179299X19860815]^ Other studies have focused on the study of single nucleotide polymorphisms (SNPs) in deciphering individual response to the chemotherapeutic drugs.^[@bibr157-1179299X19860815],[@bibr158-1179299X19860815]^ In the past, very few studies have explored the frontier of genomics in the field of biomarker discovery for chemo-resistance in advanced ovarian cancer. The major limitation of genomics approach is that the investigation of mutation and SNPs does not correlate with the level of proteins. For instance, in a previous study 12 genes were identified using DNA microarray technology; however only *HSP-10* could be validated using immunohistochemistry.^[@bibr159-1179299X19860815]^

Transcriptomics is the study of the complete set of mRNA (messenger RNA) transcripts produced by a tissue or an organism under specific conditions at a particular point in time. Messenger RNA detection and estimation have been widely used in the study of chemo-resistance in advanced ovarian cancer ([Table 3](#table3-1179299X19860815){ref-type="table"}). However, many studies have suffered from a major limitation of inaccurate correlation between gene expression and protein expression. Correlation between mRNA and protein level is insufficient to predict protein expression levels from quantitative mRNA data.^[@bibr159-1179299X19860815]^ For some genes with similar mRNA levels, the protein levels may vary by more than 20-fold and conversely, for proteins with similar levels, corresponding mRNA levels may vary by as much as 30-folds.^[@bibr160-1179299X19860815]^ Such discrepancy can be explained by taking into account post-translational events such as alternative splicing, translational regulation and differences in protein *in vivo* half-lives.^[@bibr161-1179299X19860815],[@bibr162-1179299X19860815]^

Proteomics is the study of the set of all expressed proteins in a cell, tissue or organism at a specific time under specific conditions. It can be used to characterize the flow of information in biological pathways and their networks to establish functional relevance of proteins. The proteome of a biological entity represents the dynamic relationship between the genes, environment and pathological states. Proteins are the macromolecules that are majorly affected in diseases and participate in the subsequent disease response. It is evident that proteins have the advantage to be used as biomarkers in various clinical states and to assess associated therapeutic response due to the following advantages: (a) genome is largely similar in individuals of the same species, whereas protein expression is specific to a cell type under specific conditions; (b) effect of environment is reflected in proteome more easily than genome which remains stable; (c) protein expression level is result of transcriptional activation, transcript degradation and translation efficiency and (d) proteins are the key downstream effectors and affecters in various cellular functions. Therefore, a majority of the studies have used proteomics to study the phenomenon of chemo-resistance in advanced ovarian cancer.

Post-translational modifications are important determinants of protein functionality and are an important mechanism to increase the diversity of proteome along with regulatory interactions with the various cellular functions.^[@bibr163-1179299X19860815]^ Several studies have investigated the role of post-translational modifications as potential biomarkers in cancer.^[@bibr164-1179299X19860815]^ Some post-translational modifications also play a role in chemo-response mechanisms in ovarian cancer and is summarized in [Table 4](#table4-1179299X19860815){ref-type="table"}. These modifications have an effect on cytoskeletal integrity, protein folding, metabolic function and apoptotic activity of tumour cells that in turn determines the response of ovarian cancer cells to the chemotherapeutic drug.

###### 

Effect of post-translational modifications on chemo-response carboplatin and paclitaxel in ovarian cancer.

![](10.1177_1179299X19860815-table4)

  Protein                                                                                             Post-translational modification   Effect of post-translational modification on cellular function                                            Phenotype          References
  --------------------------------------------------------------------------------------------------- --------------------------------- --------------------------------------------------------------------------------------------------------- ------------------ -------------------------------------------------------------------------------------------------------------------
  Tubulin                                                                                             De-tyrosination                   Microtubule stabilization that is essential for apoptosis                                                 Chemo-sensitive    ^[@bibr165-1179299X19860815],[@bibr166-1179299X19860815]^
  p53                                                                                                 Phosphorylation                   Leads to apoptosis                                                                                        Chemo-sensitive    ^[@bibr167-1179299X19860815],[@bibr168-1179299X19860815]^
  Tumour rejection antigen                                                                            Glycosylation                     Tumour proliferation, anti-apoptotic activity, metastasis                                                 Chemo-resistance   ^[@bibr169-1179299X19860815],[@bibr170-1179299X19860815]^
  Triose phosphate Isomerase                                                                          Glycosylation                     Facilitates glycolysis that helps to keep up with the increased energy demand in rapidly growing tumour   Chemo-resistance   ^[@bibr170-1179299X19860815],[@bibr171-1179299X19860815]^
  Palmitoyl-protein thioesterase 1 precursor                                                          Glycosylation                     Anti-apoptotic activity                                                                                   Chemo-resistance   ^[@bibr170-1179299X19860815],[@bibr172-1179299X19860815]^
  ER-associated DNAJ                                                                                  Glycosylation                     Protein folding, transport, translational initiation and gene expression                                  Chemo-resistance   ^[@bibr170-1179299X19860815],[@bibr173-1179299X19860815][@bibr174-1179299X19860815]--[@bibr175-1179299X19860815]^
  Fas-associated death domain-like interleukin-1b-converting enzyme (FLICE)-like inhibitory protein   Ubiquitination                    Suppressor of apoptosis                                                                                   Chemo-resistance   ^[@bibr176-1179299X19860815],[@bibr177-1179299X19860815]^
  Peptidyl-prolyl cis-trans isomerase A                                                               N-terminal acetylation            Conformational maintenance of oncogenes, cell proliferation, anti-apoptotic activity                      Chemo-resistance   

Biomarkers and Their Biological Functions {#section10-1179299X19860815}
=========================================

The identified genes, mRNA or proteins are involved in various biological functions such as cell cycle and checkpoint proteins, protein folding, chaperones, DNA repair proteins, cytoskeletal proteins, metabolic enzymes, transcriptional activators, drug-efflux pumps, and cellular redox protein and regulators of the apoptotic pathway as can be seen in [Table 3](#table3-1179299X19860815){ref-type="table"}.

The different mechanisms that cause chemo-resistance are explained. (a) Apoptosis is 1 of the main mechanisms employed by the cells to evade drug-induced cytotoxicity and subsequently manifest as chemo-resistance. PI3K/AKT and ERK1/2 pathway are at the centre stage of mediating anti-apoptotic activity in chemo-resistance. Various proteins interact with this pathway to prevent cell death such as increased expression of insulin-like growth factor I receptor (IGF1R), phosphatidylinositol-3-OH kinase (PIK), A-kinase anchoring protein 12 (AKAP12), chitinase 3-like 1 (CHI3L1), leptin (LEP), epithelial cell adhesion molecule (EpCam) and colony-stimulating-factor-1 receptor (CSF1R) that causes evasion of apoptosis as a downstream effect of PI3K/AKT and ERK1/2 pathway activation.^[@bibr125-1179299X19860815],[@bibr126-1179299X19860815],[@bibr127-1179299X19860815],[@bibr143-1179299X19860815],[@bibr147-1179299X19860815]^ Other proteins like cyclooxygenase-2 are known to increase production of prostaglandin E2 which is involved in resistance to apoptosis.^[@bibr119-1179299X19860815]^ Proteins like endoplasmic reticulum resident oxidoreductase 57 (ERp57) show class III β-tubulin (TUBB3) mediated anti-apoptotic activity.^[@bibr123-1179299X19860815]^ (b) Drug efflux from the cells plays an important role in the response of tumour cells to chemotherapy. Some of the interesting mechanisms include HER2 mediated increase in activity of drug-efflux pumps including the adenosine triphosphate (ATP)--binding cassette, sub-family B, member 1 (ABCB1) and ABCC3.^[@bibr14-1179299X19860815]^ Other mechanisms include increased activity of drug-transporters like lung resistance protein and ATP-driven P-glycoprotein (Pgp).^[@bibr115-1179299X19860815],[@bibr119-1179299X19860815],[@bibr132-1179299X19860815]^ (c) Cell adhesion and tumour invasion pose a challenge to the efficacy of chemotherapeutic drugs. For example, down-regulation of isoform 1 of collagen XII alpha-1 chain (COL12A1) causes extracellular matrix remoulding and tumour migration.^[@bibr132-1179299X19860815]^ Other cytoskeletal modulations include actinin alpha-4 (ACTN4) up-regulation that enhances cell motility by bundling the actin cytoskeleton causing metastasis.^[@bibr153-1179299X19860815]^ Other proteins like mesothelium vascular cell adhesion molecule-1 (VCAM1) is up-regulated in non-responders and is known to mediate tumour invasion by the epithelial and mesenchymal transition. (d) Drug metabolism is common in chemo-resistant tumour cells as an important pathway to eliminate active drug molecules and evade cytotoxic effect. Human epidermal growth factor *receptor*-2 (HER2) up-regulation increases expression of drug metabolism proteins including glutathione S-transferase P1 (GSTP1) and cytochrome P450 3A4 (CYP3A4).^[@bibr117-1179299X19860815]^ In contrast, down-regulation of thiopurine S-methyltransferase reduces the metabolism of thiopurine chemotherapeutic agents, such as 6-mercaptopurine. (e) Increase in pathways involved in tumour angiogenesis contributes to increased vascularity and nutrient supply to cells under stress condition induced by chemotherapy. For instance, up-regulation of vascular endothelial growth factor and nestin provide the tumour with a replenished microenvironment to enhance survival.^[@bibr122-1179299X19860815],[@bibr141-1179299X19860815]^ (f) Increased cell proliferation and survival pathways are an important marker for chemotherapy resistance. An interesting observation is the up-regulation of HER2 mediated activation of pro-survival proteins such as survivin, p21 and p53.^[@bibr117-1179299X19860815]^

Research has been done to understand these aspects using an array of human tissue samples. Some of the sources include ascitic fluid, serum, ovarian cancer cell lines and ovarian cancer tissue samples. A comprehensive review by Kaur and group revealed that pharmacological studies using cell lines suffer from some major drawbacks^[@bibr191-1179299X19860815]^: (a) Cell lines get genetically altered, and this sometimes alters their phenotype, native functions and their response to stimuli; (b) genotypic and phenotypic variation may occur due to serial passage of cell lines over an extended period of time and (c) unsuspected heterogeneity may occur due to genetic drift. Therefore, cell lines do not provide the actual reflection of molecular events as compared with tissue-based experiments. Also, most of the ovarian cancer cell line studies have been done for individual drugs such as cisplatin and paclitaxel, which may not correspond with the actual use of drug combinations in patients. It is of interest to note that the standard protocol for advanced ovarian cancer is a debulking surgery followed by chemotherapy. The procurement of the ovarian cancer tissue offers a window of opportunity for discovering biomarkers for innate resistance.

Studies have looked into the role of biomarkers to evaluate patient response to carboplatin and paclitaxel. This has been summarized in [Table 5](#table5-1179299X19860815){ref-type="table"}. Some of the important observations are as follows: (a) Genomic and transcriptomic studies that have been done to understand chemo-resistance to carboplatin and paclitaxel in ovarian cancer do not correspond to protein expression; (b) the chemotherapy response results from cell-cycle pathways that include apoptosis, drug-efflux mechanisms, regulation of innate immunity and cell survival; (c) observed chemo-response outcomes were mostly intrinsic by nature, indicating pre-mediated cellular mechanisms that determine clinical phenotypes and (d) metabolic proteins, chaperones, transporters, transcription regulators and cytoskeletal proteins are up-regulated in ovarian cancer tissues of patients who had chemo-resistance. Although proteomics was used to study the problem of chemo-resistance in advanced ovarian cancer, substantial progress was not made due to the absence of whole cell proteome comparison between chemo-resistant and chemo-sensitive patient tissue samples. To address this, our group has sought to delineate distinct protein signatures that could red flag an innate chemotherapy resistance in advanced ovarian cancer. In this endeavour, we employed fluorescence-based differential in-gel expression coupled with mass spectrometric analysis to identify differentially expressed proteins in the advanced ovarian cancer tissue of patients resistant and sensitive to carboplatin and paclitaxel combinations.^[@bibr114-1179299X19860815]^ Aldehyde reductase, hnRNP, cyclophilin A, heat shock protein-27 and actin that were expressed in the chemo-sensitive state are proteins intricately involved in apoptosis, and prohibitin, enoyl-coA hydratase, peroxiredoxin, fibrin-β and fibrin-γ that were expressed in the chemo-resistant state are proteins that dictate cell survival.^[@bibr225-1179299X19860815],[@bibr226-1179299X19860815]^ This clearly establishes the importance and relevance of biomarker discovery for chemo-response in ovarian cancer. This is a positive step that can pave the way for better patient management and compliance.

###### 

Biomarkers in chemo-resistance to carboplatin and paclitaxel in advanced ovarian cancer.

![](10.1177_1179299X19860815-table5)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Chemotherapy                 Macromolecule   Biomarker                                                                          Source      Cellular mechanism                                                            Clinical phenotype   Chemo-resistance   Reference
  ---------------------------- --------------- ---------------------------------------------------------------------------------- ----------- ----------------------------------------------------------------------------- -------------------- ------------------ -------------------------------------------------------------------------------------------------------------------
  Carboplatin and paclitaxel   Protein         Heat shock protein 10 (*HSP-10*) **↓**                                             Tissue      Inhibits apoptosis                                                            Non-responder        Intrinsic          ^[@bibr159-1179299X19860815]^

  Carboplatin and paclitaxel   Protein         Matrix metalloproteinase 1 (*MMP-1*) ↑                                             Tissue      Promotes tumour invasion                                                      Non-responder        Intrinsic          ^[@bibr159-1179299X19860815],[@bibr178-1179299X19860815]^

  Carboplatin and paclitaxel   *DNA*           Ecotropic virus integration site 1 protein homolog (*EVI1*) *↑*                    Tissue      Inhibits apoptosis                                                            Non-responder        Intrinsic          ^[@bibr156-1179299X19860815],[@bibr179-1179299X19860815]^

  Carboplatin and paclitaxel   *DNA*           SH3 domain-containing kinase-binding protein 1\                                    Tissue      Inhibits apoptosis                                                            Non-responder        Intrinsic          ^[@bibr156-1179299X19860815],[@bibr180-1179299X19860815]^
                                               (*CIN85*) ↓                                                                                                                                                                                                          

  Carboplatin and paclitaxel   *DNA*           Endophilin A1 (SH3GL2) **↓**                                                       Tissue      Inhibits apoptosis                                                            Non-responder        Intrinsic          ^[@bibr156-1179299X19860815],[@bibr181-1179299X19860815]^

  Carboplatin and paclitaxel   Protein         Ki-67 ↑                                                                            Tissue      Marker for increased cell proliferation                                       Responder            N/A                ^[@bibr182-1179299X19860815]^

  Carboplatin and paclitaxel   Protein         Adenosine triphosphate--binding cassette sub-family C member 2 (*ABCC2*) **↓**                 Increases apoptosis                                                           Responder            N/A                ^[@bibr182-1179299X19860815],[@bibr183-1179299X19860815]^

  Carboplatin and paclitaxel   *mRNA*          Insulin-like growth factor-1 (*IGF1*) ↑                                            Tissue      Enhances ovarian cancer cell proliferation through PI3K/Akt/mTOR signalling   Non-responder        Intrinsic          ^[@bibr184-1179299X19860815],[@bibr185-1179299X19860815]^

  Carboplatin and paclitaxel   *mRNA*          Telomerase reverse transcriptase (*TERT*) ↑                                        Tissue      Inhibits apoptosis                                                            Non-responder        Intrinsic          ^[@bibr186-1179299X19860815],[@bibr187-1179299X19860815]^

  Carboplatin and paclitaxel   *mRNA*          E2F transcription factor 1 (*E2F*) ↑                                               Tissue      Inhibits apoptosis                                                            Non-responder        Intrinsic          ^[@bibr186-1179299X19860815],[@bibr188-1179299X19860815]^

  Carboplatin and paclitaxel   *mRNA*          Cyclin-dependent kinase inhibitor 1A (CDKN1A) **↓**                                Tissue      Inhibits apoptosis                                                            Non-responder        Intrinsic          ^[@bibr186-1179299X19860815],[@bibr189-1179299X19860815]^

  Carboplatin and paclitaxel   *mRNA*          FBJ murine osteosarcoma viral oncogene homolog (*FOS*) ↑                                       Inhibits apoptosis                                                            Non-responder        Intrinsic          ^[@bibr186-1179299X19860815],[@bibr190-1179299X19860815]^

  Carboplatin and paclitaxel   *mRNA*          Tumor necrosis factor (TNF) receptor superfamily, member 10A (*TNFRSF10A*) **↓**   Tissue      Inhibits apoptosis                                                            Non-responder        Intrinsic          ^[@bibr186-1179299X19860815]^

  Carboplatin and paclitaxel   *mRNA*          TNF receptor superfamily, member 10C (TNFRSF10C) **↓**                             Tissue      Decreased activity as p53-regulated DNA damage-inducible gene                 Non-responder        Intrinsic          ^[@bibr186-1179299X19860815]^

  Carboplatin and paclitaxel   *mRNA*          TNF receptor superfamily, member 10D (TNFRSF10D) ↑                                 Tissue      Inhibits apoptosis                                                            Non-responder        Intrinsic          ^[@bibr186-1179299X19860815]^

  Carboplatin and paclitaxel   *mRNA*          TNF receptor-associated factor 1 (*TRAF-1*) **↓**                                  Tissue      Increases apoptosis                                                           Non-responder        Intrinsic          ^[@bibr186-1179299X19860815],[@bibr191-1179299X19860815]^

  Carboplatin and paclitaxel   *mRNA*          Goosecoid homeobox (*GSC*) ↑                                                       Tissue      Increases metastasis                                                          Non-responder        Intrinsic          ^[@bibr186-1179299X19860815],[@bibr192-1179299X19860815]^

  Carboplatin and paclitaxel   *mRNA*          Snail homolog 1 (*SNAI 1*) ↑                                                       Tissue      Inhibits apoptosis                                                            Non-responder        Intrinsic          ^[@bibr186-1179299X19860815],[@bibr193-1179299X19860815]^

  Carboplatin and paclitaxel   Protein         Class III β-tubulin (*TUBB3*) ↑                                                    Cell line   Cytoskeletal modulation and overcomes stress conditions                       Non-responder        Acquired           ^[@bibr194-1179299X19860815]^

  Carboplatin and paclitaxel   Protein         Lewis y ↑                                                                          Tissue      Increases cell adhesion and invasion                                          Non-responder        Intrinsic          ^[@bibr195-1179299X19860815],[@bibr196-1179299X19860815]^

  Carboplatin and paclitaxel   Protein         CD44 ↑                                                                             Tissue      Increases cell adhesion and invasion, increases drug efflux                   Non-responder        Intrinsic          ^[@bibr195-1179299X19860815][@bibr196-1179299X19860815]--[@bibr197-1179299X19860815]^

  Carboplatin and paclitaxel   Protein         CD147 ↑                                                                            Tissue      Interacts with drug resistance proteins                                       Non-responder        Intrinsic          ^[@bibr195-1179299X19860815],[@bibr198-1179299X19860815]^

  Carboplatin and paclitaxel   Protein         Human epididymis protein 4 (*HE4*) ↑                                               Tissue      Increases tumour cell proliferation                                           Non-responder        Intrinsic          ^[@bibr195-1179299X19860815],[@bibr199-1179299X19860815]^

  Carboplatin and paclitaxel   Protein         Integrin α5β1 ↑                                                                    Tissue      Increases cell adhesion and invasion                                          Non-responder        Intrinsic          ^[@bibr195-1179299X19860815],[@bibr200-1179299X19860815]^

  Carboplatin and paclitaxel   Protein         Integrin αvβ3 ↑                                                                    Tissue      Increases cell adhesion and invasion                                          Non-responder        Intrinsic          ^[@bibr195-1179299X19860815],[@bibr201-1179299X19860815]^

  Carboplatin and paclitaxel   Protein         CD44 ↑                                                                             Tissue      Increases cell adhesion and invasion, increases drug efflux                   Non-responder        Intrinsic          ^[@bibr196-1179299X19860815],[@bibr197-1179299X19860815],[@bibr202-1179299X19860815]^

  Carboplatin and paclitaxel   Protein         IL-8 ↑                                                                             Tissue      Inhibits apoptosis                                                            Non-responder        Intrinsic          ^[@bibr202-1179299X19860815],[@bibr203-1179299X19860815]^

  Carboplatin and paclitaxel   Protein         α-Enolase (*ENO1*) ↑                                                               Tissue      Cytoskeleton modulation and inhibition of apoptosis                           Non-responder        Intrinsic          ^[@bibr114-1179299X19860815],[@bibr204-1179299X19860815][@bibr205-1179299X19860815]--[@bibr206-1179299X19860815]^

  Carboplatin and paclitaxel   Protein         Enoyl CoA hydratase (*ECH*) ↑                                                      Tissue      Decreases apoptosis                                                           Non-responder        Intrinsic          ^[@bibr114-1179299X19860815],[@bibr207-1179299X19860815]^

  Carboplatin and paclitaxel   Protein         Prohibitin (*PHB*) ↑                                                               Tissue      Inhibits apoptosis                                                            Non-responder        Intrinsic          ^[@bibr114-1179299X19860815],[@bibr208-1179299X19860815]^

  Carboplatin and paclitaxel   Protein         Peroxiredoxin-4 (*PRDX4*) ↑                                                        Tissue      Overcomes stress condition and inhibits apoptosis                             Non-responder        Intrinsic          ^[@bibr114-1179299X19860815],[@bibr209-1179299X19860815],[@bibr210-1179299X19860815]^

  Carboplatin and paclitaxel   Protein         Fibrin β ↑                                                                         Tissue      Increases tumour angiogenesis and inhibits apoptosis                          Non-responder        Intrinsic          ^[@bibr114-1179299X19860815],[@bibr211-1179299X19860815][@bibr212-1179299X19860815]--[@bibr213-1179299X19860815]^

  Carboplatin and paclitaxel   Protein         Fibrin γ ↑                                                                         Tissue      Increases tumour angiogenesis and inhibits apoptosis                          Non-responder        Intrinsic          ^[@bibr114-1179299X19860815],[@bibr211-1179299X19860815][@bibr212-1179299X19860815]--[@bibr213-1179299X19860815]^

  Carboplatin and paclitaxel   Protein         Heat shock protein-27 (*HSP27*) ↑                                                  Tissue      Increases apoptosis and reduces drug efflux                                   Responder            Intrinsic          ^[@bibr114-1179299X19860815],[@bibr214-1179299X19860815],[@bibr215-1179299X19860815]^

  Carboplatin and paclitaxel   Protein         Actin (*ACT*) ↑                                                                    Tissue      Increases apoptosis                                                           Responder            Intrinsic          ^[@bibr114-1179299X19860815],[@bibr216-1179299X19860815],[@bibr217-1179299X19860815]^

  Carboplatin and paclitaxel   Protein         Heterogeneous ribonucleoprotein particle (*hnRNP*) ↑                               Tissue      Increases apoptosis                                                           Responder            Intrinsic          ^[@bibr114-1179299X19860815],[@bibr218-1179299X19860815],[@bibr219-1179299X19860815]^

  Carboplatin and paclitaxel   Protein         Aldose reductase (*ALDR*) ↑                                                        Tissue      Increases apoptosis                                                           Responder            Intrinsic          ^[@bibr114-1179299X19860815],[@bibr220-1179299X19860815],[@bibr221-1179299X19860815]^

  Carboplatin and paclitaxel   Protein         α-enolase (*ENO1*) ↑                                                               Tissue      Cytoskeleton modulation and inhibition of apoptosis                           Non-responder        Intrinsic          ^[@bibr204-1179299X19860815][@bibr205-1179299X19860815]--[@bibr206-1179299X19860815],[@bibr222-1179299X19860815]^

  Carboplatin and paclitaxel   Protein         Elongation factor Tu mitochondrial\                                                Tissue      Regulation of autophagy and innate immunity                                   Non-responder        Intrinsic          ^[@bibr222-1179299X19860815]^
                                               (*TUFM*) ↑                                                                                                                                                                                                           

  Carboplatin and paclitaxel   Protein         Glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) ↑                               Tissue      Increases glycolysis enhancing cell survival                                  Non-responder        Intrinsic          ^[@bibr222-1179299X19860815],[@bibr223-1179299X19860815]^

  Carboplatin and paclitaxel   Protein         Stress-70 protein mitochondrial\                                                   Tissue      Inhibits apoptosis                                                            Non-responder        Intrinsic          ^[@bibr222-1179299X19860815],[@bibr224-1179299X19860815]^
                                               (*GRP75*) ↑                                                                                                                                                                                                          

  Carboplatin and paclitaxel   Protein         Annexin A 1 (*ANXA1*) ↑                                                            Tissue      Overcomes stress and inhibits apoptosis                                       Non-responder        Intrinsic          ^[@bibr222-1179299X19860815]^
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Conclusions {#section11-1179299X19860815}
===========

Clinical research for chemotherapy combinations in advanced ovarian cancer has progressed over the years with a view to achieve better CR and tolerability. Currently, carboplatin and paclitaxel combination is widely used to treat advanced ovarian cancer globally. Even though there has been significant improvement in the CR and OS, a large proportion of the patients relapse due to chemo-resistance. A lot of progress has been made in the fields of genomics, transcriptomics and proteomics to understand the molecular processes that determine and dictate chemotherapy response. Clinical proteomics holds a lot of promise for biomarker discovery that can pave the way for development of diagnostics that can help monitor chemotherapeutics in patients with advanced ovarian cancer.
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